LV11468B - 5-lipoxygenase inhibitors - Google Patents
5-lipoxygenase inhibitors Download PDFInfo
- Publication number
- LV11468B LV11468B LVP-95-313A LV950313A LV11468B LV 11468 B LV11468 B LV 11468B LV 950313 A LV950313 A LV 950313A LV 11468 B LV11468 B LV 11468B
- Authority
- LV
- Latvia
- Prior art keywords
- alkyl
- tetrahydro
- pyran
- compound
- mmol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Claims (13)
- LV 11468 Izgudrojuma formula 1. Savienojums ar formulu R Ar1 — X1 Ar — X1 — Ar3 R un tā farmaceitiski pieņemamās sālis, kur: Ar1 ir heterocikliska palieka no grupas: imidazolilgrupa, pirolilgrupa, pira-zolilgrupa, 1,2,3-triazolilgrupa, 1,2,4-triazolilgrupa, indolilgrupa, ind-azolilgrupa, benzimidazolilgrupa, kas pievienota pie X1 ar gredzena slāpekļa atomu, un ir neobligāti aizvietota ar vienu vai diviem aizvietotājiem no grupas: halogēna atoms, hidroksilgrupa, ciāngrupa, aminogrupa, C-^-alkilgrupa, C-,.4-alkoksigrupa, C^-alkiltiogrupa, halo-gēnaizvietota C^-alkilgrupa, halogēnaizvietota C^-alkoksigrupa, C-,.4-alkilaminogrupa un (C^-alkilgrupa^N-; X1 ir vienkāršā saite vai C-,.4-alkilēngrupa; Ar2 ir fenilēngrupa, kas neobligāti aizvietota ar vienu vai diviem aizvietotājiem no grupas: halogēna atoms, hidroksilgrupa, ciāngrupa, aminogru- 1 pa, Cļ-4-alkilgrupa, C^-alkoksigrupa, C^-alkiltiogrupa, halogēnaizvie-tota Cļ-4-alkilgrupa, halogēnaizvietota C^-alkoksigrupa; X2 ir -Α-Χ- vai -Χ-Α-, kur A ir vienkāršā saite vai C^-alkilēngrupa un X ir O, S, SO vai S02; Ar3 ir fenilēngrupa, piridilēngrupa, tienilēngrupa, furilēngrupa, oksazolilēn-grupa vai tiazolilēngrupa, neobligāti aizvietota ar vienu vai diviem aizvietotājiem no grupas: halogēna atoms, hidroksilgrupa, ciāngrupa, aminogrupa, C^-alkilgrupa, C^-alkoksigrupa, C^-alkiltiogrupa, halogēnaizvietota Cļ^-alkilgrupa, halogēnaizvietota C^-alkoksigrupa, C^-alkilaminogrupa un (C^-alkilgrupaJsN-; R1 un R2 , neatkarīgi viens no otra, ir Cļ^-alkilgrupa, vai arī abi kopā veido grupu ar formulu -D1-Z-D2-, kas kopā ar to oglekļa atomu, kuram tā pievienota, veido 3-8 atomu ciklu, kurā D1 un D2 ir C^-alkilēngrupa un Z ir vienkāršā saite, 0, S, SO, S02 vai vinilēngrupa, pie tam D1 un D2 var būt aizvietoti ar C-,.3-alkilgrupu; Y ir CONR3R4, CN, COOR3, COR3 vai CSNR3R4, kur R3 un R4 , neatkarīgi viens no otra, ir H vai C^-alkilgrupa.
- 2. Savienojums pēc 1. punkta,kurā Ar3 ir neobligāti aizvietota fenilēngrupa.
- 3. Savienojums pēc 2. punkta, kurā Ar2 ir 1,4-fenilēngrupa un Ar3 ir 1,3-fenilēngrupa vai 5-fluor-1,3-fenilēngrupa.
- 4. Savienojums pēc 3. punkta, kurā Ar1 ir 2-alkilimidazolilgrupa un X1 ir vienkāršā saite.
- 5. Savienojums pēc 4. punkta, kurā Y ir C0NH2.
- 6. Savienojums pēc 5. punkta, kurā R1 un R2 ir D1-Z-D2, kur D1 un D2 katrs ir etilēngrupa un Z ir O.
- 7. Savienojums pēc 6. punkta, kurā Ar1 ir 2-metilimidazolilgrupa un X2 ir CH20.
- 8. Savienojums pēc 6. punkta, kurā Ar1 ir 2-metilimidazolilgrupa un X2 ir S.
- 9. Savienojums pēc 3. punkta, kurā Ar1 ir pirolilgrupa, X1 ir CH2 , X2 ir S un Y ir CONH2. 2 LV 11468
- 10. Savienojums pec 1. punkta, proti, savienojums no grupas: 4-{5-fluor-3-[4-(2-metilimidazol-1-il)benziloksi]fenil}-3,4,5,6-tetrahidro-2H-pirāna-4-karbonskābes amīds; 4-{3[4-(2-metilimidazol-1-il)feniltio]fenil}-3,4,5,6-tetrahidro-2H-pirāna-4-karbonskābes amīds; 4-{3[4-(pirol-1-ilmetil)feniltio]fenil}-3,4,5,6-tetrahidro-2H-pirāna-4-karbonskābes amīds.
- 11. Farmaceitiskā kompozīcija alerģiska vai iekaisuma stāvokļa ārstēšanai zīdītājā, kas satur terapeitiski darbīgu daudzumu savienojuma pēc 1. punkta un farmaceitiski pieņemamu nesēju.
- 12. Savienojuma pēc 1. punkta pielietojums medikamenta ražošanai, kas paredzēts tādu slimīgu stāvokļu ārstēšanai zīdītājā, kuros nepieciešams pielietot 5-lipoksigenāzes inhibitoru.
- 13. Pielietojums pēc 12. punkta, kurā minētais slimīgais stāvoklis ir alerģisks vai iekaisuma stāvoklis. 3
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9401747 | 1994-10-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV11468A LV11468A (lv) | 1996-08-20 |
| LV11468B true LV11468B (en) | 1996-12-20 |
Family
ID=14098722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-95-313A LV11468B (en) | 1994-10-18 | 1995-10-17 | 5-lipoxygenase inhibitors |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP0787127B1 (lv) |
| JP (1) | JP3032579B2 (lv) |
| CN (1) | CN1093536C (lv) |
| AT (1) | ATE198474T1 (lv) |
| AU (1) | AU681520B2 (lv) |
| BG (1) | BG61768B1 (lv) |
| CA (1) | CA2202057C (lv) |
| CO (1) | CO4480026A1 (lv) |
| CZ (1) | CZ287350B6 (lv) |
| DE (1) | DE69519804T2 (lv) |
| DK (1) | DK0787127T3 (lv) |
| ES (1) | ES2153033T3 (lv) |
| FI (1) | FI971632A (lv) |
| GR (1) | GR3035471T3 (lv) |
| HU (1) | HU221543B (lv) |
| IL (1) | IL115581A (lv) |
| LV (1) | LV11468B (lv) |
| MY (1) | MY114680A (lv) |
| NO (1) | NO314629B1 (lv) |
| NZ (1) | NZ285163A (lv) |
| PE (1) | PE49196A1 (lv) |
| PL (1) | PL180104B1 (lv) |
| RU (1) | RU2136666C1 (lv) |
| SI (1) | SI9500392A (lv) |
| SK (1) | SK281577B6 (lv) |
| TR (1) | TR199501274A2 (lv) |
| TW (1) | TW411339B (lv) |
| UA (1) | UA45312C2 (lv) |
| WO (1) | WO1996011911A1 (lv) |
| YU (1) | YU65995A (lv) |
| ZA (1) | ZA958748B (lv) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6239285B1 (en) | 1998-02-06 | 2001-05-29 | Pfizer Inc | Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| US6194585B1 (en) * | 1998-12-22 | 2001-02-27 | Pfizer Inc. | Process for preparing 5-lipoxygenase inhibitors |
| US6346624B1 (en) * | 1999-08-31 | 2002-02-12 | Pfizer Inc | Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| US6344563B1 (en) | 1999-08-31 | 2002-02-05 | Timothy Norris | Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| SG87145A1 (en) * | 1999-08-31 | 2002-03-19 | Pfizer Prod Inc | Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| ES2398093T3 (es) * | 2000-03-24 | 2013-03-13 | Euro-Celtique S.A. | Pirazoles, triazoles y tetrazoles sustituidos con arilo como bloqueantes de los canales de sodio |
| CA2444735C (en) * | 2001-04-20 | 2012-10-23 | Novozymes A/S | Lipoxygenase |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| UA92833C2 (en) | 2006-11-27 | 2010-12-10 | Пфайзер Продактс Инк. | Pyrazole analogues |
| EA201000703A1 (ru) * | 2007-11-26 | 2010-12-30 | Пфайзер Инк. | Производные пиразола в качестве ингибиторов 5-lo |
| CN104144920A (zh) * | 2012-02-28 | 2014-11-12 | 皮拉马尔企业有限公司 | 作为gpr促效剂的苯基烷酸衍生物 |
| HRP20220331T1 (hr) | 2018-03-08 | 2022-05-13 | Incyte Corporation | Spojevi aminopirazin diola kao inhibitori pi3k-y |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0462830B1 (en) * | 1990-06-21 | 1995-10-18 | Zeneca Limited | Cyclic ether derivatives |
| IE913866A1 (en) * | 1990-11-28 | 1992-06-03 | Ici Plc | Aryl derivatives |
| EP0505122A1 (en) * | 1991-03-21 | 1992-09-23 | Zeneca Limited | Alpha, alpha-dialkylbenzyl derivatives |
| EP0540165A1 (en) * | 1991-10-03 | 1993-05-05 | Zeneca Limited | Alkanoic acid derivatives |
| AU685122B2 (en) * | 1993-06-14 | 1998-01-15 | Pfizer Inc. | Imidazole lipoxygenase inhibitors |
-
1994
- 1994-10-18 SK SK1287-95A patent/SK281577B6/sk unknown
-
1995
- 1995-05-29 JP JP8513058A patent/JP3032579B2/ja not_active Expired - Fee Related
- 1995-05-29 NZ NZ285163A patent/NZ285163A/en unknown
- 1995-05-29 DE DE69519804T patent/DE69519804T2/de not_active Expired - Fee Related
- 1995-05-29 PL PL95319727A patent/PL180104B1/pl not_active IP Right Cessation
- 1995-05-29 AT AT95918121T patent/ATE198474T1/de not_active IP Right Cessation
- 1995-05-29 HU HU9701853A patent/HU221543B/hu not_active IP Right Cessation
- 1995-05-29 EP EP95918121A patent/EP0787127B1/en not_active Expired - Lifetime
- 1995-05-29 CZ CZ19971177A patent/CZ287350B6/cs not_active IP Right Cessation
- 1995-05-29 WO PCT/IB1995/000408 patent/WO1996011911A1/en active IP Right Grant
- 1995-05-29 ES ES95918121T patent/ES2153033T3/es not_active Expired - Lifetime
- 1995-05-29 CN CN95195926A patent/CN1093536C/zh not_active Expired - Fee Related
- 1995-05-29 DK DK95918121T patent/DK0787127T3/da active
- 1995-05-29 RU RU97106099/04A patent/RU2136666C1/ru not_active IP Right Cessation
- 1995-05-29 AU AU24174/95A patent/AU681520B2/en not_active Ceased
- 1995-05-29 CA CA002202057A patent/CA2202057C/en not_active Expired - Fee Related
- 1995-09-12 TW TW084109522A patent/TW411339B/zh not_active IP Right Cessation
- 1995-10-02 CO CO95045652A patent/CO4480026A1/es unknown
- 1995-10-12 IL IL11558195A patent/IL115581A/xx not_active IP Right Cessation
- 1995-10-13 UA UA95104510A patent/UA45312C2/uk unknown
- 1995-10-16 MY MYPI95003103A patent/MY114680A/en unknown
- 1995-10-17 PE PE1995282113A patent/PE49196A1/es not_active Application Discontinuation
- 1995-10-17 ZA ZA958748A patent/ZA958748B/xx unknown
- 1995-10-17 YU YU65995A patent/YU65995A/sh unknown
- 1995-10-17 SI SI9500392A patent/SI9500392A/sl unknown
- 1995-10-17 LV LVP-95-313A patent/LV11468B/en unknown
- 1995-10-18 TR TR95/01274A patent/TR199501274A2/xx unknown
- 1995-10-18 BG BG100070A patent/BG61768B1/bg unknown
-
1997
- 1997-04-17 NO NO19971773A patent/NO314629B1/no unknown
- 1997-04-17 FI FI971632A patent/FI971632A/fi not_active IP Right Cessation
-
2001
- 2001-02-23 GR GR20010400310T patent/GR3035471T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5883106A (en) | 5-lipoxygenase inhibitors | |
| LV11468B (en) | 5-lipoxygenase inhibitors | |
| US7691843B2 (en) | N-hydroxyamide derivatives possessing antibacterial activity | |
| US4999378A (en) | Phenylcarboxylic acid derivatives | |
| US6063928A (en) | 5-lipoxygenase inhibitors | |
| US5753682A (en) | Imidazole lipoxygenase inhibitors | |
| JP3400392B2 (ja) | ５−リポキシゲナーゼ阻害剤及び新規医薬組成物 | |
| EP0446798A1 (en) | 1-alkyl-, 1-alkenyl- and 1-alkynylaryl-2-amino-1, 3-propanediols and related compounds, a process and intermediates for their preparation and their use as medicaments | |
| JP2843920B2 (ja) | イミダゾールリポキシゲナーゼ阻害剤 | |
| KR100239930B1 (ko) | 5-리폭시게나제 저해제 | |
| PT787127E (pt) | Inibidores de 5-lipoxigenase |